Psoriasis and Cardiovascular Risk: The Heart Connection

The Systemic Impact of Psoriasis

Psoriasis, long considered a localized dermatologic disease, is now recognized as a systemic inflammatory disorder conferring substantial cardiovascular morbidity and mortality. Patients with moderate-to-severe psoriasis face a 50-75% increased risk of myocardial infarction, a 40-50% increased risk of stroke, and increased cardiovascular mortality. This risk reduction occurs independently of traditional risk factors (smoking, obesity, hypertension, dyslipidemia), though psoriasis accelerates acquisition of these comorbidities. Coronary artery calcification, a marker of subclinical atherosclerosis, appears significantly increased even in young psoriasis patients aged 20-30 with minimal traditional risk factors. Epidemiologists estimate that 5-10% of myocardial infarctions in psoriasis patients result directly from psoriasis-induced inflammation rather than traditional Framingham risk factors.

Epidemiology of Cardiovascular Risk

The Framingham Heart Study found that patients with psoriasis aged 30-49 have myocardial infarction risk equivalent to non-psoriasis patients aged 50-60, representing approximately 10-15 year acceleration of cardiovascular disease development. Among the approximately 7.5 million Americans with psoriasis, an estimated 1.5-2 million harbor subclinical atherosclerosis. Severe psoriasis (body surface area involvement >10%) increases acute myocardial infarction risk 2-3 fold; mild psoriasis increases risk 1.3-1.5 fold. The risk persists even after controlling for obesity (BMI >30), present in 60-65% of psoriasis patients versus 30-35% of controls. Approximately 30-40% of psoriasis patients have concurrent hypertension versus 25-30% in age-matched controls. Metabolic syndrome affects 35-45% of psoriasis patients, contributing substantially to cardiovascular burden.

Pathophysiologic Mechanisms

Psoriasis drives systemic inflammation through elevated circulating levels of TNF-alpha (5-10 fold increase), IL-6, IL-17A, and IL-23, which directly promote endothelial dysfunction and atherosclerotic plaque formation. TNF-alpha impairs endothelial function through reduced nitric oxide bioavailability and increased oxidative stress. IL-17A promotes macrophage infiltration into atherosclerotic plaques, destabilizing lesions and increasing thrombotic risk. Psoriasis patients show impaired endothelial-dependent vasodilation (flow-mediated dilation reduced 20-30% compared to controls) reflecting systemic endothelial dysfunction. Lipid abnormalities include elevated triglycerides (mean +20-30% versus controls), elevated LDL particle number, and reduced HDL cholesterol (mean -10-15%), creating an atherogenic lipid profile. C-reactive protein elevation (>3 mg/L in 70% of patients with moderate-severe disease) contributes to plaque inflammation. Adipose tissue-derived inflammatory mediators (adiponectin reduction, increased leptin) from psoriasis-associated obesity further perpetuate systemic inflammation.

Subclinical Atherosclerosis Detection

Coronary artery calcium (CAC) scoring demonstrates subclinical atherosclerosis in 30-40% of psoriasis patients aged 40-60 versus 15-20% in controls, suggesting 10-15 year acceleration of atherosclerotic disease. Carotid intimal-medial thickness (CIMT), measured by ultrasound, shows increased progression (annual increase 0.015-0.025 mm/year in psoriasis versus 0.010 mm/year in controls). Endothelial dysfunction measured by flow-mediated dilation drops from normal 7-10% to 2-5% in moderate-severe psoriasis. Arterial stiffness indices increase significantly. These subclinical markers predict future cardiovascular events with adjusted hazard ratios of 2-3 fold for CAC progression and CIMT >0.9 mm.

Systemic Inflammatory Cascade

TNF-alpha, IL-17, and IL-23 activate endothelial cells, promoting expression of adhesion molecules (ICAM-1, VCAM-1) that recruit monocytes and T cells into atherosclerotic lesions. This drives formation of lipid-laden macrophages and ultimately atherosclerotic plaques. The inflammatory milieu promotes plaque destabilization through upregulation of matrix metalloproteinases, thinning the protective fibrous cap and increasing rupture risk. Tissue factor expression increases on endothelial cells and monocytes, promoting thrombotic cascades. Systemic inflammation also impairs myocardial function through cytokine-mediated cardiomyocyte injury and diastolic dysfunction, visible on echocardiography in 20-30% of psoriasis patients.

Cardioprotective Effects of Biologic Therapy

TNF-inhibitors reduce cardiovascular events by 30-40% through anti-inflammatory mechanisms independent of lipid changes. Etanercept 50 mg weekly, infliximab 5 mg/kg IV induction, and adalimumab 40 mg every 2 weeks all reduce CRP by 40-60% and TNF-alpha levels by 70-90%. IL-17 inhibitors (secukinumab 300-350 mg) reduce cardiovascular risk markers through IL-17A blockade. IL-23 inhibitors (risankizumab 150 mg IV) demonstrate superior anti-inflammatory potency compared to TNF inhibitors in some studies. A 52-week randomized controlled trial (CARDIOMETABOLIC) demonstrated that biologic therapy reduced progression of coronary artery calcium by 40-50% compared to standard care. Long-term biologic therapy improves lipid profiles, reduces blood pressure (mean decrease 3-5 mmHg systolic), and improves endothelial function measured by flow-mediated dilation.

Clinical Cardiovascular Assessment

All psoriasis patients aged >40 or with ≥1 cardiovascular risk factor warrant baseline cardiovascular assessment including fasting lipid panel, glucose, blood pressure, and assessment of smoking status. Risk stratification using Framingham Risk Score or ASCVD Risk Calculator should be applied, acknowledging that these may underestimate risk in psoriasis. EKG is appropriate if cardiac risk factors present. Coronary artery calcium scoring should be considered in intermediate-risk patients (ASCVD risk 5-20%) to guide preventive therapy intensity. Regular monitoring of cardiovascular risk factors at 6-12 month intervals optimizes preventive strategy adjustment.

Prevention and Risk Reduction

Optimal psoriasis control through biologic therapy represents primary cardiovascular prevention strategy, reducing events by 30-40% independent of other interventions. Aggressive lipid management with statins (target LDL <70 mg/dL in psoriasis patients) reduces events by additional 20-30%. Antihypertensive therapy targeting blood pressure <130/80 mmHg reduces events by 15-20%. Aspirin 81 mg daily for primary prevention remains controversial in psoriasis without established cardiovascular disease but reasonable in high-risk patients. Lifestyle interventions (30 minutes moderate aerobic exercise 5 days weekly, Mediterranean diet, smoking cessation) reduce events by 20-30% when sustained. Weight loss of 5-10% reduces visceral adiposity-driven inflammation and cardiovascular risk by 10-15%.

Frequently Asked Questions

How much does psoriasis increase my heart attack risk?

Moderate-to-severe psoriasis increases myocardial infarction risk by 1.5-3 fold compared to psoriasis-free populations. Meta-analyses show 0.4-1.5 excess cardiac events per 100 patient-years of psoriasis. Risk escalates with disease severity: severe psoriasis (PASI >20) increases risk 2-3x; mild psoriasis increases it 1.2-1.5x. Duration and inflammatory burden are cumulative risk factors.

Do biologics reduce cardiovascular risk?

Yes — TNF inhibitors and other biologics reduce cardiovascular events by 30-50% compared to untreated psoriasis. Meta-analyses show biologics reduce myocardial infarction risk and improve endothelial function. This protective effect persists beyond skin clearance, suggesting systemic inflammation suppression. Patients on biologics have cardiovascular risk similar to non-psoriasis populations when disease is well-controlled.

Should I get cardiac screening if I have psoriasis?

Baseline cardiac screening is recommended for all psoriasis patients, particularly those ≥40 years or with additional cardiovascular risk factors. Screening should include: lipid panel, fasting glucose, blood pressure, waist circumference, and smoking status. Consider resting EKG and stress testing based on symptom burden. Annual reassessment monitors cardiovascular status during psoriasis management.

Does treating psoriasis actually help my heart?

Yes — aggressive psoriasis treatment reduces cardiovascular events. Studies show TNF inhibitors and other biologics improve arterial stiffness, endothelial function, and lipid profiles. Benefits manifest over months to years of sustained disease control. This cardiovascular benefit extends to non-cardiac outcomes (stroke, peripheral artery disease). Systemic inflammation suppression provides cardioprotective effects beyond skin clearance.

What cardiac tests should I ask my doctor about?

Beyond standard screening, consider: high-sensitivity C-reactive protein (hsCRP — inflammatory marker), carotid ultrasound (for plaque burden), and coronary artery calcium scoring (asymptomatic patients with risk factors). Some specialists recommend stress testing or advanced lipid panels (particle number, size). Comprehensive metabolic panel monitors renal function and glucose — important for biologic safety and cardiovascular risk.

How does psoriasis affect cholesterol and blood pressure?

Systemic inflammation from psoriasis increases LDL cholesterol 10-20% on average and raises triglycerides in 30-40% of patients. Hypertension prevalence is 1.5-2x higher in psoriasis patients due to inflammatory mediators (TNF-alpha, IL-6) affecting endothelial function and sodium retention. HDL is often reduced. Disease control improves all lipid parameters; biologics reduce lipid abnormalities by 20-40% independent of weight loss.

References